What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

Cees G. M. Kallenberg*, Arjan Vissink, Frans G. M. Kroese, Wayel H. Abdulahad, Hendrika Bootsma

*Bijbehorende auteur voor dit werk

    Onderzoeksoutputpeer review

    30 Citaten (Scopus)
    213 Downloads (Pure)


    In vitro and in vivo experimental data have pointed to new immunopathogenic mechanisms in primary Sjögren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. This has taught us that the role of proinflammatory cytokines, in particular TNFα, is not crucial in the immunopathogenesis of pSS. B cells appear to play a major role, as depletion of B cells leads to restoration of salivary flow and is efficacious for treatment of extraglandular manifestations and mucosa-associated lymphoid tissue lymphoma. B cells also orchestrate T-cell infiltration and ductal epithelial dearrangement in the salivary glands. Gene profiling of salivary gland tissue in relation to B-cell depletion confirms that the axis of IFNα, B-cell activating factor, B-cell activation, proliferation and survival constitutes a major pathogenic route in pSS.

    Originele taal-2English
    Aantal pagina's8
    TijdschriftArthritis Research and Therapy
    Nummer van het tijdschrift1
    StatusPublished - 28-feb-2011

    Citeer dit